These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23474038)

  • 1. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
    Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
    Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.
    Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Barisoni L; Jennette CJ; Bragat A; Castelli J; Sitaraman S; Lockhart DJ; Boudes PF
    Orphanet J Rare Dis; 2012 Nov; 7():91. PubMed ID: 23176611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
    Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
    PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migalastat: A Review in Fabry Disease.
    McCafferty EH; Scott LJ
    Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
    Nowak A; Huynh-Do U; Krayenbuehl PA; Beuschlein F; Schiffmann R; Barbey F
    J Inherit Metab Dis; 2020 Mar; 43(2):326-333. PubMed ID: 31449323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
    Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
    Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
    Benjamin ER; Della Valle MC; Wu X; Katz E; Pruthi F; Bond S; Bronfin B; Williams H; Yu J; Bichet DG; Germain DP; Giugliani R; Hughes D; Schiffmann R; Wilcox WR; Desnick RJ; Kirk J; Barth J; Barlow C; Valenzano KJ; Castelli J; Lockhart DJ
    Genet Med; 2017 Apr; 19(4):430-438. PubMed ID: 27657681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
    Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
    Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
    Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
    Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
    Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
    N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
    Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
    Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in Fabry disease: the combination of two individually amenable
    Fernandes RM; Bento D; Marques N; Azevedo O; Mota T; Costa H; Santo ME; Silva DC; Jesus I
    Future Cardiol; 2023 Jan; 19(1):39-43. PubMed ID: 36695159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review and recommendations for oral chaperone therapy in adult patients with Fabry disease.
    Nowicki M; Bazan-Socha S; Błażejewska-Hyżorek B; Kłopotowski MM; Komar M; Kusztal MA; Liberek T; Małyszko J; Mizia-Stec K; Oko-Sarnowska Z; Pawlaczyk K; Podolec P; Sławek J;
    Orphanet J Rare Dis; 2024 Jan; 19(1):16. PubMed ID: 38238782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy.
    Lamari F; Mauhin W; Koraichi F; Khrouf W; Bordet C; London J; Lidove O; Charron P
    Mol Genet Genomic Med; 2019 Sep; 7(9):e894. PubMed ID: 31393666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.
    Majid H; Verma N; Bhandari S; Gupta S; Nidhi
    Expert Opin Pharmacother; 2024 Apr; 25(6):769-782. PubMed ID: 38753367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
    Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.